Abstract
INTRODUCTION
We investigated the prevalence of amyloid beta (Aβ) positivity (+) and cognitive trajectories in Koreans and non-Hispanic Whites (NHWs).
METHODS
We included 5121 Koreans from multiple centers across South Korea and 929 NHWs from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Participants underwent Aβ positron emission tomography and were categorized into cognitively unimpaired (CU), mild cognitive impairment (MCI), and dementia stages. Age, sex, education, and apolipoprotein E. genotype were adjusted using multivariable logistic regression and stabilized inverse probability of treatment weights based on the propensity scores to mitigate imbalances in these variables.
RESULTS
The prevalence of Aβ+ was lower in CU Koreans than in CU NHWs (adjusted odds ratio 0.60). Aβ+ Koreans showed a faster cognitive decline than Aβ+ NHWs in the CU (B = −0.314, p = .004) and MCI stages (B = −0.385, p < .001).
DISCUSSION
Ethnic characteristics of Aβ biomarkers should be considered in research and clinical application of Aβ-targeted therapies in diverse populations.
HIGHLIGHTS
Koreans have a lower prevalence of Aβ positivity compared to NHWs in the CU stage.
The effects of Alzheimer’s risk factors on Aβ positivity differ between Koreans and NHWs.
Aβ-positive (Aβ+) Koreans show faster cognitive decline than Aβ+ NHWs in the CU and MCI stages.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Hyemin Jang,
Min Young Chun,
Jihwan Yun,
Jun Pyo Kim,
Sung Hoon Kang,
Michael Weiner,
Hee Jin Kim,
Duk L. Na,
Chang‐Hyung Hong,
Sang Joon Son,
Hyun Woong Roh,
Tae‐Kyeong Lee,
Eek‐Sung Lee,
Eun Hye Lee,
Daeun Shin,
Hongki Ham,
Yuna Gu,
Yeshin Kim,
Chi‐Hun Kim,
Sook‐young Woo,
Sang Won Seo,
the ADNI, A4 study, and K‐ROAD study groups | September 24, 2024